Composition and method for inhibiting the proliferation of enterotoxigenic Bacteroides fragilis

Siphoviridae bacteriophages, particularly Bac-FRP-5, address the ineffectiveness of antibiotics against antibiotic-resistant ETBF by specifically targeting and killing ETBF, providing a safe and effective treatment for associated diseases.

KR103046037B1Active Publication Date: 2026-11-10INTRON BIOTECHNOLOGY INC
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
KR1020237036094
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Priority Date
2021-04-10
Filing Date
2022-03-23
Publication Date
2026-11-10
Estimated Expiration
2042-03-23

AI Technical Summary

Technical Problem

Existing treatments for enterotoxigenic Bacteroides fragilis (ETBF) infections, particularly antibiotics, are becoming less effective due to antibiotic resistance, and there is a need for a more specific and safer alternative to prevent or treat diseases caused by ETBF without disrupting beneficial symbiotic bacteria.

Method used

A composition comprising Siphoviridae bacteriophages, specifically bacteriophage Bac-FRP-5, which has a unique genome sequence (SEQ ID NO. 1) and structural proteins, is used to lyse ETBF cells, formulated with pharmaceutically acceptable carriers, and administered to prevent or treat ETBF infections.

Benefits of technology

The Siphoviridae bacteriophages, particularly Bac-FRP-5, effectively target and kill ETBF with high specificity, reducing the risk of side effects by preserving beneficial bacteria, and are effective in preventing or treating acute and chronic intestinal diseases, diarrhea, enteritis, colon neoplasms, and cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 112023115419909-PCT00008_ABST
    Figure 112023115419909-PCT00008_ABST
Patent Text Reader

Abstract

A composition for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis comprises a Siphoviridae bacteriophage (Bac-FRP-5) having the ability to lyse enterotoxigenic Bacteroides fragilis cells and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis comprises the steps of: administering a Siphoviridae bacteriophage to a subject; and lysing enterotoxigenic Bacteroides fragilis cells with the Siphoviridae bacteriophage.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] This application claims priority to U.S. Final Patent Application No. 17 / 227,287 filed April 10, 2021, which is incorporated by reference as fully described herein for all purposes.

[0002] The present invention relates to enterotoxinogenic Bacteroides fragilis ( Bacteroides fragilis The present invention relates to a composition and method for inhibiting the proliferation of ), more specifically, a composition comprising Siphoviridae bacteriophages and a method for using the same. Background Technology

[0003] Bacteroides ( Bacteroides ) Species account for nearly half of the fecal microbiota population and are important host symbionts for nutrition, mucosal function, and systemic immunity. Among the Bacteroides species, Bacteroides fragilis ( Bacteroides fragilis ; B. Fragilis ( B. fragilis The strain is an opportunistic pathogen. Enterotoxigenic Bacteroides fragilis (ETBF) is Bacteroides fragilis It can produce proteolytic endotoxins named BFT or fragilysin, which cause diarrheal excretion and colonic epithelial damage. ETBF has emerged over the past 35 years as the conventional etiology of diarrheal diseases accompanied by enteritis in animals and humans (Clin. Microbiol. Rev. 22: 349-369, 2009). The association between chronic intestinal disease and ETBF has been established for over 20 years, and ETBF is also benignly associated with ulcerative colitis and colonic neoplasms (Gut Pathog. 9: 53-59, 2017; BMC Canc. 19: 879-882, 2019).

[0004] Furthermore, ETBF can induce cancers such as colorectal cancer (CRC). CRC is one of the most common cancers, accounting for approximately 10% of all cancer cases and 8% of all cancer deaths. BFT is known to bind to colon epithelial cells (CECs) and stimulate the cleavage of the tumor suppressor protein, E-cadherin. E-cadherin cleavage increases intestinal barrier permeability and enhances cell signaling through the β-catenin / Wnt pathway, which is essentially activated by congenital expression in all CRCs. As a result, BFT stimulates the proliferation and migration of human colon cancer cells in vitro (Gastroenterology 124: 392-400, 2003). Data indicating the ability of BFT to further activate the nuclear factor-kappa B (NF-κB) pathway, which induces pro-inflammatory cytokine secretion by CECs, and that specific NF-κB pools encourage the initiation and promotion of epithelial tumorigenic mechanisms, led to the hypothesis that ETBF is a pro-inflammatory oncogenic colon bacterium. This hypothesis was supported by a recent small study in Türgière, which suggested that ETBF colony formation was more frequent in patients with CRC than in controls without CRC (Clin. Microbiol. Infect. 12: 782-786, 2006).

[0005] Generally, antibiotics are used to treat infectious diseases of ETBF. However, the efficacy of antibiotics is continuously decreasing due to the increase in antibiotic-resistant ETBF, and there is a need to develop more effective methods other than currently prescribed antibiotics.

[0006] Recently, the use of bacteriophages as a countermeasure against bacterial infectious diseases has garnered significant attention. Bacteriophages are very small microorganisms that infect bacteria and are commonly referred to simply as "phages." Once a bacteriophage infects a bacterial cell, it multiplies within the cell. After multiplication, the bacteriophage's offspring destroy the bacterial cell wall and are released from the host bacterium, indicating that the bacteriophage has the ability to kill bacteria. The manner in which bacteriophages infect bacteria is characterized by their very high specificity, which limits the number of bacteriophage types that infect specific bacteria. In other words, specific bacteriophages can only infect specific bacteria, demonstrating that they can kill only those specific bacteria and cannot harm other bacteria. Due to this bacterial specificity, bacteriophages provide antimicrobial effects only against target bacteria and do not invade commensal bacteria in animals, including humans. Conventional antibiotics, which have been widely used to treat bacteria, incidentally affect many types of bacteria. This causes problems such as disturbance of the normal bacterial flora. On the other hand, the use of bacteriophages does not disturb the normal bacterial flora because they selectively kill target bacteria. Therefore, bacteriophages can be used safely, thereby significantly reducing the probability of side effects compared to any other antibiotic.

[0007] Due to their unique ability to kill bacteria, bacteriophages have attracted attention as a potential effective countermeasure against bacterial infections since their discovery, and there is a lot of research related to this.

[0008] Bacteriophages tend to be highly specific to bacteria. Bacteriophage attacks have been found to be specific, meaning that a single bacteriophage species targets only a single bacterial species (or even a specific strain within that species). Furthermore, the antimicrobial activity of bacteriophages can be said to be dependent on the strain type of the target bacteria. Therefore, it is necessary to collect many types of bacteriophages useful for effectively controlling specific bacteria. Thus, to develop effective methods for using bacteriophages that respond to ETBF, it is necessary to secure many types of bacteriophages that exhibit antimicrobial activity against ETBF. Moreover, the generated bacteriophages need to be screened to determine whether they are superior to others in terms of antimicrobial activity and antimicrobial spectrum. The problem to be solved

[0009] Therefore, the present invention was made with the problems experienced in the relevant technical field in mind and aims to solve these problems. means of solving the problem

[0010] In one embodiment, a composition for preventing or treating an infection or disease caused by ETBF comprises a Siphoviridae bacteriophage having the ability to lyse ETBF cells and a pharmaceutically acceptable carrier.

[0011] In another embodiment, the bacteriophage has a genome comprising the sequence described in SEQ ID NO. 1; or (1) a sequence having at least 90% lookup range with at least 90% similarity to SEQ ID NO. 1, (2) a circular genome shape, and (3) a genome having 64 open read frames.

[0012] In another embodiment, the siphoviridae bacteriophage is 1 × 10 1 pfu / mL to 1× 10⁻⁶ 30 pfu / mL or 1 × 10⁻⁶ 1 pfu / g to 1× 10 30It has a concentration of pfu / g.

[0013] In another embodiment, the siphoviridae bacteriophage is 1 × 10 4 pfu / mL to 1× 10⁻⁶ 15 pfu / mL or 1 × 10⁻⁶ 4 pfu / g to 1× 10 15 It has a concentration of pfu / g.

[0014] In another embodiment, the pharmaceutically acceptable carrier is lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, or mineral oil.

[0015] In another embodiment, the composition further comprises one or more selected from the group consisting of lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, and preservatives.

[0016] In another embodiment, the infection or disease caused by ETBF is acute and chronic intestinal disease, bacteremia, diarrhea, enteritis, colon neoplasm, or cancer. The cancer is colorectal cancer or colon cancer, but is not limited thereto.

[0017] In another embodiment, the composition is a solution, suspension, emulsion, extract, powder, granule, tablet, or capsule in an oily or water-soluble medium.

[0018] In another embodiment, the composition further comprises a second bacteriophage having the ability to lyse ETBF bacterial species, and the second bacteriophage has a genome having a sequence having a lookup range of less than 90% with at least 90% similarity to SEQ ID NO. 1.

[0019] In another embodiment, the sifobiridae bacteriophage has major structural proteins of approximately 42 kDa, 48 kDa, 63 kDa, 65 kDa, 75 kDa, 88 kDa, and 118 kDa sizes.

[0020] In another embodiment, the siphoviridae bacteriophage has a latent period of 10 to 100 minutes and a release amount of 150 to 540 PFU / infected cell.

[0021] In another embodiment, the incubation period is 40 to 80 minutes, and the release amount is 200 to 450 PFU / infected cell.

[0022] In one embodiment, a method for preventing or treating an infection or disease caused by ETBF comprises the steps of: administering a siphoviridae bacteriophage to a subject; and dissolving ETBF into a siphoviridae bacteriophage.

[0023] In another embodiment, the siphoviridae bacteriophage comprises the sequence described in SEQ ID NO. 1.

[0024] In another embodiment, the siphoviridae bacteriophage is 1 × 10 1 pfu / mL to 1× 10⁻⁶ 30 pfu / mL or 1 × 10⁻⁶ 1 pfu / g to 1× 10 30 It has a concentration of pfu / g.

[0025] In another embodiment, the siphoviridae bacteriophage is 1 × 10 4 pfu / mL to 1× 10⁻⁶ 15 pfu / mL or 1 × 10⁻⁶ 4 pfu / g to 1× 10 15 It has a concentration of pfu / g.

[0026] The foregoing general description and the following detailed description are all illustrative and interpretive and should be understood as providing further explanation of the invention as claimed. Effects of the invention

[0027] The composition and method for inhibiting the proliferation of ETBF according to the present application possess high specificity against ETBF compared to conventional antibiotic-based compositions and methods. The present composition can be used to prevent or treat ETBF without affecting other beneficial symbiotic bacteria, and has fewer side effects. Generally, when antibiotics are used, symbiotic bacteria are also damaged, leading to various side effects. Meanwhile, individual antimicrobial properties such as antimicrobial activity and antimicrobial range (host range) in bacteriophages differ even among bacteriophages exhibiting antimicrobial activity against the same bacterial species, and typically, bacteriophages are effective against only some bacterial strains within the same species. Therefore, the composition and method according to the present application provide different effects in their industrial applications. Brief explanation of the drawing

[0028] The attached drawings are included to provide a further understanding of the present invention and are incorporated into this specification to form part of it, presenting embodiments of the present invention and explaining the principles of the present invention together with the detailed description. Figure 1 is an electron microscope image showing the morphology of the bacteriophage Bac-FRP-5. Figure 2 shows the results of the analysis of the major structural proteins of bacteriophage Bac-FRP-5. Figure 3 is a photograph showing the experimental results regarding the ability of bacteriophage Bac-FRP-5 to kill ETBF. The clear area is a plaque formed by the lysis of the target bacteria. Figure 4 is the one-step growth curve of bacteriophage Bac-FRP-5. Specific details for implementing the invention

[0029] Embodiments of the present invention will now be described in detail, and examples thereof are shown in the attached drawings.

[0030] According to one aspect of the present invention, the present invention provides a bacteriophage named Bac-FRP-5, which has the ability to specifically kill ETBF and has a genome comprising the sequence described in SEQ ID NO. 1. In some embodiments, the bacteriophage comprises a genome having all of the following features: (1) a sequence having at least 90% lookup range with at least 90% agreement with SEQ ID NO. 1, (2) a circular genome shape, and (3) 64 open templates; a genome having all of the following features: (1) a sequence having at least 92% lookup range with at least 90% agreement with SEQ ID NO. 1, (2) a circular genome shape, and (3) 64 open templates; a genome having all of the following features: (1) a sequence having at least 94% lookup range with at least 90% agreement with SEQ ID NO. 1, (2) a circular genome shape, and (3) 64 open templates. Or, it includes a genome having all of the following features: (1) a sequence having at least 96% search range with at least 90% similarity to sequence number 1, (2) a circular genome shape, and (3) 64 open decoding frames.

[0031] The present invention also provides a method for preventing or treating an infection or disease caused by ETBF using a composition containing the same as an active ingredient.

[0032] Bacteriophage Bac-FRP-5 was isolated by the inventors and deposited at the National Institute of Biotechnology and Bioengineering, Biological Resource Center on December 9, 2020 (Accession No.: KCTC 14403 BP).

[0033] The molecular weights of the major structural proteins of bacteriophage Bac-FRP-5 are approximately 42 kDa, 48 kDa, 63 kDa, 65 kDa, 75 kDa, 88 kDa, and 118 kDa.

[0034] The incubation period and release amount of bacteriophage Bac-FRP-5 are 10 to 100 minutes and 150 to 540 PFU / infected cells, respectively, preferably 40 to 80 minutes and 200 to 450 PFU / infected cells, respectively, but are not limited thereto.

[0035] In addition, the present invention provides a composition applicable to the prevention or treatment of an infection or disease caused by ETBF, comprising bacteriophage Bac-FRP-5 as an active ingredient.

[0036] Since the bacteriophage Bac-FRP-5 included in the composition of the present invention effectively kills ETBF, it is considered to be effective in preventing ETBF infection or treating diseases caused by ETBF. Therefore, the composition of the present invention can be used for the prevention and treatment of diseases caused by ETBF.

[0037] In the present invention, diseases induced by ETBF include, but are not limited to, acute and chronic intestinal diseases, bacteremia, diarrhea, enteritis, colon neoplasms, or cancer.

[0038] Pharmaceutically acceptable carriers included in the composition of the present invention are generally those used in the manufacture of pharmaceutical formulations, examples thereof include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, or mineral oil, but are not limited thereto. In addition to the above components, the composition of the present invention may additionally include lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, and preservatives.

[0039] In the composition of the present invention, bacteriophage Bac-FRP-5 is included as an active ingredient. Bacteriophage Bac-FRP-5 is 1 × 10⁻⁶1 pfu / mL to 1× 10⁻⁶ 30 pfu / mL or 1 × 10⁻⁶ 1 pfu / g to 1× 10 30 A concentration of pfu / g, preferably 1 × 10⁻⁶ 4 pfu / mL to 1× 10⁻⁶ 15 pfu / mL or 1 × 10⁻⁶ 4 pfu / g to 1× 10 15 It is included at a concentration of pfu / g.

[0040] The composition of the present invention may be formulated using pharmaceutically acceptable carriers and / or excipients in single-dose or multi-dose containers according to methods that can be easily performed by those skilled in the art to which the present invention pertains. Next, the formulation may be in the form of a solution, suspension or emulsion, extract, powder, granule, tablet, or capsule in an oily or water-soluble medium. A dispersing agent or a stabilizer may be additionally included.

[0041] To improve the efficacy of the above purpose, a bacteriophage having antimicrobial activity against bacterial species other than ETBF may be additionally included in the composition of the present invention. Additionally, other types of bacteriophages having antimicrobial activity against ETBF may be additionally included in the composition of the present invention. Since the antimicrobial properties of bacteriophages, such as antimicrobial activity and antimicrobial range (host range), differ even among bacteriophages exhibiting antimicrobial activity against the same bacterial species, such bacteriophages may be additionally included to maximize the antimicrobial effect.

[0042] In this specification, the terms “prevention” and “prevent” refer to (i) blocking ETBF infection; and (ii) inhibiting the progression of a disease caused by ETBF infection.

[0043] In this specification, the terms “treatment” and “treat” refer to any activity that (i) suppresses a disease caused by ETBF and (ii) alleviates the pathological state of a disease caused by ETBF.

[0044] In this specification, the terms “disease caused by ETBF” and “ETBF infection” refer to, but are not limited to, acute and chronic intestinal diseases, bacteremia, diarrhea, enteritis, colon neoplasms, or cancer.

[0045] In this specification, the term "latency period" refers to the time required for bacteriophage particles to reproduce within an infected host cell.

[0046] In this specification, the term "release amount" refers to the number of bacteriophages produced per infected bacterium.

[0047] In this specification, the terms "isolate," "isolating," and "isolated" refer to the activity of isolating bacteriophages from nature by applying various experimental techniques and obtaining characteristics that distinguish the target bacteriophage from others, and additionally include the activity of propagating the target bacteriophage using biotechnological techniques so that the target bacteriophage can be industrially applied.

[0048] In this detailed description, the terms "search range" and "match" relate to BLAST (basic local sort search tool), an online search tool provided by NCBI (National Center for Biotechnology Information).

[0049] In this detailed description, the lookup range is a number describing the extent to which the lookup sequence (i.e., the genome sequence of bacteriophage Bac-FRP-5) is included in the target sequence (i.e., the genome sequence of a previously reported bacteriophage). If the target sequence of the database is included in the entire lookup sequence, the lookup range is 100%. To the inventors, this indicates the lengths of the sequences relative to each other.

[0050] In this detailed description, the terms "agreement" or "sequence agreement" are measured over a lookup range and are numbers describing the degree of similarity between a lookup sequence (i.e., the genome sequence of bacteriophage Bac-FRP-5) and a target sequence (i.e., the genome sequence of a previously reported bacteriophage). More specifically, the terms "agreement" or "sequence agreement" refer to the percentage of matching nucleotides in the corresponding sequence portions of the target sequence (i.e., the genome sequence of the previously reported bacteriophage) or the lookup sequence (i.e., the genome sequence of bacteriophage Bac-FRP-5) when the lookup sequence (i.e., the genome sequence of bacteriophage Bac-FRP-5) and the target sequence (i.e., the genome sequence of the previously reported bacteriophage) are analyzed by BLAST alignment analysis. The higher the agreement percentage, the more significant the match. From the above definitions of "query range" and "percentage of agreement," it will be obvious to a person skilled in the art that the difference in "query range" and / or "percentage of agreement" between the genomes of two similar bacteriophages creates a difference in the number of ORFs (open sequence frames) arranged in the two genomes, and subsequently leads to distinct characteristics of the two similar bacteriophages (range of target strains and strength of antimicrobial activity).

[0051] In this detailed description, the term “second bacteriophage” refers to any bacteriophage having the ability to specifically kill ETBF, having a sequence with at least 90% similarity to SEQ ID NO. 1 and having a lookup range of less than 90%, and having characteristics different from bacteriophage Bac-FRP-5 in terms of genome shape and number of ORFs, wherein the genome of the second bacteriophage is of a linear shape.

[0052] A practical and currently preferred embodiment of the present invention is described as shown in the following examples.

[0053] However, those skilled in the art will understand that modifications and improvements can be made within the spirit and scope of the present invention in consideration of the present invention.

[0054] Example 1: Isolation of a bacteriophage capable of killing ETBF

[0055] To isolate bacteriophages capable of killing ETBF, samples were collected from environmental or clinical samples. In this invention, the ETBF strain used for the isolation of the bacteriophage was previously isolated and identified as ETBF by the inventors.

[0056] The procedure for isolating bacteriophages is described in detail herein. The collected sample was added to BHIB (brain-heart infusion culture) culture medium (calf brain infusion from 200 g, 7.7 g / L; bovine heart infusion from 250 g, 9.8 g / L; proteose peptone, 10 g / L; dextrose, 2 g / L; sodium chloride, 5 g / L; disodium phosphate, 2.5 g / L) inoculated with ETBF at a ratio of 1 / 100, and then incubated statically at 37°C for 2 days under anaerobic conditions. Upon completion of incubation, centrifugation was performed at 8,000 rpm for 20 minutes, and the supernatant was recovered. The recovered supernatant was inoculated with ETBF at a ratio of 1 / 100, and then incubated statically at 37°C for 2 days under anaerobic conditions. When the sample contained bacteriophages, the above procedure was repeated a total of 5 times to sufficiently increase the number (potency) of bacteriophages. After repeating the procedure 5 times, the culture solution was centrifuged at 8,000 rpm for 20 minutes. After centrifugation, the recovered supernatant was filtered using a 0.45 μm filter. The obtained filtrate was used in a typical spot assay to investigate whether it contained bacteriophages capable of killing ETBF.

[0057] The spot assay was performed as follows: ETBF was inoculated into BHIB culture medium at a ratio of 1 / 100 and subsequently incubated statically at 37°C for 2 days under anaerobic conditions. 2 mL of the above-mentioned (OD 600The ETBF culture solution of 1.5) was spread onto a BHIA plate (calf brain infusion from 200 g, 7.7 g / L; bovine heart infusion from 250 g, 9.8 g / L; proteose peptone, 10 g / L; dextrose, 2 g / L; sodium chloride, 5 g / L; disodium phosphate, 2.5 g / L; agar, 15 g / mL). The plate was placed on a clean bench for about 30 minutes to dry the spread solution. After drying, 10 μL of the prepared filtrate was applied onto the ETBF-spreading plate culture medium and allowed to dry for about 30 minutes. After drying, the plate culture medium with the applied filtrate was incubated at 37°C for 2 days under anaerobic conditions, and then the formation of a clear area at the location where the filtrate was applied was examined. In the case of the filtrate in which a transparent region was generated, it was determined that it contained a bacteriophage capable of killing ETBF. Through the above examination, it was possible to obtain a filtrate containing a bacteriophage capable of killing ETBF.

[0058] Pure bacteriophages were isolated from the filtrate verified above to contain bacteriophages capable of killing ETBF. A conventional plaque assay was used to isolate the pure bacteriophages. Specifically, the plaque formed during the plaque assay was recovered using a sterile tip, added to the ETBF culture solution, and subsequently incubated at 37°C for 2 days under anaerobic conditions. After incubation, centrifugation was performed at 8,000 rpm for 20 minutes to obtain the supernatant. The ETBF culture solution was added to the obtained supernatant at a volume ratio of 1 / 50 and subsequently incubated at 37°C for 2 days under anaerobic conditions. To increase the number of bacteriophages, the above procedure was repeated at least 5 times. Next, centrifugation was performed at 8,000 rpm for 20 minutes to obtain the final supernatant. The plaque assay was further performed using the generated supernatant. Generally, the isolation of pure bacteriophages is not completed in a single repetition of the procedure, so the procedure was repeated using the resulting plaques formed above. After at least five repetitions of the procedure, a solution containing pure bacteriophages was obtained. The procedure for isolating pure bacteriophages was generally repeated until the generated plaques became similar in size and shape. In addition, the final isolation of pure bacteriophages was verified using an electron microscope. Electron microscopy observations were performed according to conventional methods. Briefly, a solution containing pure bacteriophages was loaded onto a copper grid, then negatively stained with 2% uranyl acetate, and dried. Next, its morphology was observed using a transmission electron microscope. An electron microscope image of the isolated pure bacteriophages is shown in Figure 1. Based on morphological characteristics, the isolated novel bacteriophages were verified to belong to the Siphoviridae family of bacteriophages.

[0059] The solution containing the verified pure bacteriophage above underwent the following purification process. ETBF culture solution was added to the solution containing the pure bacteriophage at a volume ratio of 1 / 50 relative to the total volume of the bacteriophage solution, and subsequently cultured for an additional 2 days under anaerobic conditions. After culture, centrifugation was performed at 8,000 rpm for 20 minutes to obtain the supernatant. To obtain a solution containing a sufficient number of bacteriophages, this procedure was repeated a total of 5 times. The supernatant obtained from the final centrifugation was filtered using a 0.45 μm filter and subsequently subjected to a conventional polyethylene glycol (PEG) precipitation process. Specifically, PEG and NaCl were added to 100 mL of the filtrate to a concentration of 10% PEG 8000 / 0.5 M NaCl, and then left at 4°C for 2 to 3 hours. Then, centrifugation was performed at 8,000 rpm for 30 minutes to obtain a bacteriophage precipitate. The resulting bacteriophage precipitate was suspended in 5 mL of buffer (10 mM Tris-HCl, 10 mM MgSO4, 0.1% gelatin, pH 8.0). The resulting substance was referred to as the bacteriophage suspension or bacteriophage solution.

[0060] As a result, the pure bacteriophage purified above was collected, named bacteriophage Bac-FRP-5, and deposited with the National Institute of Biotechnology and Bioengineering, Biological Resource Center on December 9, 2020 (Accession No.: KCTC 14403 BP).

[0061] Example 2: Isolation and Sequencing of the Genome of Bacteriophage Bac-FRP-5

[0062] The genome of bacteriophage Bac-FRP-5 was isolated as follows. The genome was isolated from the bacteriophage suspension obtained using the same method as in Example 1. First, to remove the DNA and RNA of ETBF contained in the suspension, 200 U of DNase I and RNase A, respectively, were added to 10 mL of the bacteriophage suspension and incubated at 37°C for 30 minutes. After incubation for 30 minutes, 500 μL of 0.5 M ethylenediaminetetraacetic acid (EDTA) was added to stop the activity of DNase I and RNase A, and the mixture was incubated for 10 minutes. Additionally, the resulting mixture was incubated at 65°C for an additional 10 minutes, after which 100 μL of protease K (20 mg / mL) was added to break the outer wall of the bacteriophage, and the mixture was subsequently reacted at 37°C for 20 minutes. Subsequently, 500 μL of 10% sodium dodecyl sulfate (SDS) was added, and the mixture was reacted at 65°C for 1 hour. After the 1-hour reaction, 10 mL of a solution of phenol:chloroform:isoamyl alcohol mixed in a component ratio of 25:24:1 was added to the reaction solution and mixed thoroughly. Additionally, the resulting mixture was centrifuged at 13,000 rpm for 15 minutes to separate the layers. Among the separated layers, the supernatant was selected, and isopropyl alcohol was added to it at a volume ratio of 1.5. The mixture was then centrifuged at 13,000 rpm for 10 minutes to precipitate the genome. After collecting the precipitate, 70% ethanol was added to the precipitate, and the precipitate was washed by centrifuging at 13,000 rpm for 10 minutes. The washed precipitate was recovered, vacuum-dried, and then dissolved in 100 μL of water. This procedure was repeated to obtain a sufficient amount of the genome of bacteriophage Bac-FRP-5.

[0063] Information regarding the genome sequence of bacteriophage Bac-FRP-5 obtained above was acquired by performing next-generation sequencing analysis using the Illumina Mi-Seq instrument from the Seoul National University Center for Agriculture and Life Sciences. Finally, the analyzed genome of bacteriophage Bac-FRP-5 has a size of 46,506 bp, and the sequence of the entire genome is represented as SEQ ID NO. 1.

[0064] The homology (similarity) between the previously reported bacteriophage genome sequences and the bacteriophage Bac-FRP-5 genome sequence obtained above was investigated using BLAST search. The bacteriophage Bac-FRP-5 genome sequence is Bacteroides It was found to have relatively high homology with the sequence of bacteriophage B40-8 culture collection site ATCC 51477-B1 (GenBank accession number FJ008913.1) (query range: 34%, sequence agreement: 87.71%). Furthermore, while the number of open sequence frames (ORFs) on the bacteriophage Bac-FRP-5 genome is 64, Bacteroides The bacteriophage culture collection organ ATCC 51477-B1 has 46 open decoding frames.

[0065] Based on these results, it is determined that bacteriophage Bac-FRP-5 is undoubtedly a novel bacteriophage distinct from commonly reported bacteriophages. Additionally, since the antimicrobial activity and spectrum of bacteriophages typically depend on the bacteriophage type, it is considered that bacteriophage Bac-FRP-5 may provide antimicrobial activity different from any other previously reported bacteriophages.

[0066] Example 3: Analysis of major structural proteins of bacteriophage Bac-FRP-5

[0067] The major structural proteins of bacteriophage Bac-FRP-5 were analyzed by performing one-dimensional electrophoresis. To obtain the proteins constituting the outer wall of bacteriophage Bac-FRP-5, 200 μL of the bacteriophage suspension prepared in Example 1 was mixed with 800 μL of acetone and vigorously vortexed. The mixture was left to stand at -20°C for 10 minutes. Centrifugation was performed at 13,000 rpm at 4°C for 20 minutes to remove the supernatant, followed by air drying. The precipitate was resuspended in 50 μL of electrophoresis sample buffer (5×) and then heated for 5 minutes. The prepared sample was analyzed by one-dimensional electrophoresis. As a result, as shown in Figure 2, major structural proteins of approximately 42 kDa, 48 kDa, 63 kDa, 65 kDa, 75 kDa, 88 kDa, and 118 kDa were verified.

[0068] Example 4: Investigation of the ability of bacteriophage Bac-FRP-5 to kill ETBF

[0069] The ability of bacteriophage Bac-FRP-5 to kill ETBFs was investigated. To investigate the killing ability, the formation of a clear region was observed using the spot assay method in the same manner as described in Example 1. A total of five strains identified as ETBF strains were used as ETBFs for the investigation of killing ability. Bacteriophage Bac-FRP-5 had the ability to lyse and kill a total of three strains out of the five ETBFs used as experimental targets. The experimental results are presented in Table 1, and representative results are shown in Figure 3.

[0070]

[0071] On the other hand, bacteriophage Bac-FRP-5 is Bordetella bronchiceptica ( Bordetella bronchiseptica ), Enterococcus faecalis ( Enterococcus faecalis ), Enterococcus faecium ( Enterococcus faecium ), Staphilococcus aureus ( Staphylococcus aureus ), Streptococcus pneumoniae ( Sreptococcus pneumonia ), E. coli ( E. coli ) and Pseudomonas eruginosa ( Pseudomonas aeruginosa The ability to kill ) was also investigated in a separate experiment. As a result, bacteriophage Bac-FRP-5 did not have the ability to kill these bacteria.

[0072] Therefore, bacteriophage Bac-FRP-5 has been verified to possess a potent ability to kill ETBF and a broad antimicrobial spectrum against ETBF, suggesting that bacteriophage Bac-FRP-5 can be used as an active ingredient in compositions for preventing and treating ETBF infections.

[0073] Example 5: Growth characteristics of bacteriophage Bac-FRP-5

[0074] The growth characteristics of bacteriophage Bac-FRP-5 were analyzed by analyzing the one-stage growth curve. The analysis of the one-stage growth curve of bacteriophage Bac-FRP-5 was performed as follows: ETBF was inoculated into 50 mL of BHIB (Brain-Heart Infusion Medium, Diphcosa) culture medium at a ratio of 1 / 100, followed by the logarithmic growth phase (OD 600 Static culture was performed under anaerobic conditions until the value was 0.4 to 0.5. Upon completion of culture, the bacterial cell pellet was recovered by centrifugation at 8,000 rpm for 5 minutes. The recovered pellet was suspended in 50 mL of BHIB. The resulting material may be referred to as the bacterial suspension. Bacteriophage Bac-FRP-5 was mixed with the bacterial suspension at a multiple infection factor (MOI) of 0.1, incubated at room temperature for 10 minutes, and then centrifuged at 12,000 rpm for 30 seconds. After removing the supernatant, the pellet containing the bacteriophage-infected bacterial cells was suspended in 50 mL of BHIB and incubated at 37°C without shaking. Aliquots were collected at 20-minute intervals for 140 minutes, and the titer of the aquots was immediately determined by the conventional plaque assay (Fig. 4).

[0075] The incubation period of bacteriophage Bac-FRP-5 was estimated to be approximately 60 ± 10 minutes, and the average release was estimated to be about 320 ± 100 pfu / infected cell.

[0076] Example 6: Experimental example regarding the prevention of ETBF infection using bacteriophage Bac-FRP-5

[0077] 100 μL of bacteriophage Bac-FRP-5 suspension (1 × 10⁻⁶ 8 pfu / mL) was added to a tube containing 9 mL of BHIB culture medium. An equal amount of BHIB culture medium was additionally added to another tube containing 9 mL of BHIB culture medium. Next, a culture solution of the ETBF strain (CCARM 18106 strain) was added to each tube until the absorbance at 600 nm reached approximately 0.5. After adding ETBF, the tubes were moved to an incubator at 37°C and subsequently cultured statically while observing the growth of ETBF. As shown in Table 2, it was observed that the growth of ETBF was inhibited in the tubes with the bacteriophage Bac-FRP-5 suspension, whereas the growth of ETBF was not inhibited in the tubes without the bacteriophage suspension.

[0078]

[0079] The above results indicate that the bacteriophage Bac-FRP-5 of the present invention not only inhibits the growth of ETBF but also possesses the ability to kill ETBF. Therefore, it is determined that the bacteriophage Bac-FRP-5 can be used as an active ingredient in a composition for preventing ETBF infection.

[0080] Example 7: Preventive effect of bacteriophage Bac-FRP-5 on ETBF infection in an animal model

[0081] The preventive effect of bacteriophage Bac-FRP-5 on weaning pigs infected with ETBF was investigated. Four 25-day-old weaning pigs were grouped together, and a total of two groups of pigs were housed in separate pig crates (1.1 m × 1.0 m). A heating system was installed, and the surrounding environment was controlled. The temperature and humidity of the pig crates were maintained constant, and the floors were cleaned daily. Starting from day 1 of the experiment, pigs in the experimental group (with added bacteriophage) were fed 1 × 10⁶ according to the standard feeding procedure. 8 Pigs were reared on feed supplemented with bacteriophage Bac-FRP-5 at pfu / g, whereas pigs in the control group (without bacteriophage supplementation) were reared on the same feed without bacteriophage Bac-FRP-5 according to standard procedures. Starting from day 7 of the experiment, the feed for all experimental groups was 1 × 10⁶ 8 ETBF infection was induced by contaminating the experimental and control groups with pfu / g of ETBF for 2 days and administering the suspension twice daily, respectively. The administered ETBF suspension was prepared as follows: The ETBF strain (CCARM 18110) was cultured anaerobically in BHIB culture medium at 37°C for 2 days, and subsequently, the bacteria were isolated and 10 [units of volume] were sterilized using physiological saline (pH 7.2). 9 It was adjusted to cfu / mL. Starting the day after feeding the contaminated feed for 2 days (Day 9 of the experiment), pigs in the experimental group (with added bacteriophages) were fed 1 × 10⁶ uncontaminated feeds according to the previous standard feeding procedure. 8The pigs were reared again using feed supplemented with bacteriophage Bac-FRP-5 at pfu / g, whereas the control group (pigs without bacteriophage supplementation) were reared using the same feed without bacteriophage supplementation according to standard procedures. Starting from day 9 of the experiment, diarrhea tests were performed on all test animals daily. The severity of diarrhea was determined by measuring the diarrhea index. The diarrhea index was measured using the commonly used fecal consistency (FC) score (normal: 0 points, soft feces: 1 point, loose diarrhea: 2 points, severe diarrhea: 3 points). The results are shown in Table 3.

[0082]

[0083] From the above results, it was verified that the bacteriophage Bac-FRP-5 of the present invention can be very effective in inhibiting ETBF infection.

[0084] Example 8: Example of treatment of infectious disease of ETBF using bacteriophage Bac-FRP-5

[0085] The therapeutic effect of bacteriophage Bac-FRP-5 on diseases induced by ETBF was evaluated as follows: Forty 8-week-old mice were divided into two groups of 20 mice each; subsequently, five mice from each subgroup were reared separately in individual mouse boxes, and the experiment was conducted for 7 days. On the second day of the experiment, 0.1 mL of ETBF suspension was administered to all mice via intraperitoneal injection. The administered BTBF suspension was prepared as follows: The ETBF strain (CCARM 18110) was cultured anaerobically in BHIB medium at 37°C for 2 days, and subsequently, the bacteria were isolated and 10 [units of volume] was sterilized using physiological saline (pH 7.2). 9 It was adjusted to cfu / mL. 2 hours after administration of ETBF, 10 9pfu's bacteriophage Bac-FRP-5 was administered via intraperitoneal injection to mice in the experimental group (administered the bacteriophage suspension). 0.1 mL of saline solution was administered via intraperitoneal injection to mice in the control group (not administered the bacteriophage suspension). Both the control and experimental groups were fed feed and water, and were raised equally. The survival of the mice was observed from the administration of ETBF until the end of the test. The results are shown in Table 4 below.

[0086]

[0087] As is evident from the above results, the bacteriophage Bac-FRP-5 of the present invention can be judged to be highly effective in the treatment of diseases induced by ETBF.

[0088] Those skilled in the art will understand that the concepts and specific embodiments disclosed in the foregoing detailed description can be readily used as a basis for modifying or designing other embodiments to perform the same purpose as the present invention. Furthermore, those skilled in the art will understand that such equivalent embodiments do not depart from the spirit and scope of the present invention as described in the appended claims.

[0089] It will be obvious to those skilled in the art that various modifications and alterations to the present invention can be made without departing from the spirit or scope of the invention. Accordingly, the present invention is intended to encompass modifications and alterations of the invention as long as they fall within the scope of the appended claims and their equivalents.

[0090] Depository Name: Korea Research Institute of Biotechnology and Bioengineering Biological Resource Center (KCTC) Trustee Number: KCTC14403BP Date of Deposit: 2020-12-09

Claims

Claim 1 Enterotoxigenic Bacteroides fragilis ( Bacteroides fragilis A composition for preventing or treating an infection or disease caused by ), wherein the enterotoxigenic bacteroides fragilis A composition comprising: a Siphoviridae bacteriophage Bac-FRP-5 having the ability to lyse cells and a genome containing the sequence described in SEQ ID NO. 1 (Korea Research Institute of Biotechnology and Bioengineering, Center for Biological Resources, Accession No.: KCTC 14403 BP); and a pharmaceutically acceptable carrier. wherein the Siphoviridae bacteriophage Bac-FRP-5 has a latent period of 10 to 100 minutes and a release rate of 150 to 540 plaque-forming units (PFU) / infected cell, the Siphoviridae bacteriophage Bac-FRP-5 has structural proteins of sizes 42 kDa, 48 kDa, 63 kDa, 65 kDa, 75 kDa, 88 kDa, and 118 kDa, and the concentration of the Siphoviridae bacteriophage Bac-FRP-5 is 1 × 10⁻¹⁰ 4 PFU / mL ~ 1×10 15 PFU / mL or 1×10⁻⁶ 4 PFU / g ~ 1×10 15 PFU / g, and the above infection or disease is diarrhea, enteritis, or colon cancer. Claim 2 delete Claim 3 delete Claim 4 delete Claim 5 A composition according to claim 1, wherein the pharmaceutically acceptable carrier is lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, or mineral oil. Claim 6 A composition according to claim 1, further comprising one or more selected from the group consisting of lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, and preservatives. Claim 7 delete Claim 8 The composition according to claim 1, wherein the composition is a solution, suspension, emulsion, extract, powder, granule, tablet, or capsule in an oily or water-soluble medium. Claim 9 delete Claim 10 delete Claim 11 delete Claim 12 A composition according to claim 1, further comprising a second bacteriophage having the ability to lyse enterotoxigenic Bacteroides fragilis bacterial species, wherein the second bacteriophage has a genome different from SEQ ID NO.

1. Claim 13 delete Claim 14 delete Claim 15 delete Claim 16 delete

Citation Information

Patent Citations

  • Prebiotic compositions comprising one or more types of bacteriophage

    US20150297648A1